NZ597975A - Methods and compositions for use in cellular therapies - Google Patents

Methods and compositions for use in cellular therapies

Info

Publication number
NZ597975A
NZ597975A NZ597975A NZ59797510A NZ597975A NZ 597975 A NZ597975 A NZ 597975A NZ 597975 A NZ597975 A NZ 597975A NZ 59797510 A NZ59797510 A NZ 59797510A NZ 597975 A NZ597975 A NZ 597975A
Authority
NZ
New Zealand
Prior art keywords
compositions
methods
cellular therapies
medicament
therapies
Prior art date
Application number
NZ597975A
Other languages
English (en)
Inventor
Eleuterio Lombardo
Dirk Buscher
Original Assignee
Tigenix S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tigenix S A filed Critical Tigenix S A
Publication of NZ597975A publication Critical patent/NZ597975A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
NZ597975A 2009-07-09 2010-07-09 Methods and compositions for use in cellular therapies NZ597975A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22427509P 2009-07-09 2009-07-09
PCT/IB2010/001968 WO2011004264A1 (en) 2009-07-09 2010-07-09 Methods and compositions for use in cellular therapies

Publications (1)

Publication Number Publication Date
NZ597975A true NZ597975A (en) 2014-06-27

Family

ID=42782196

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ597975A NZ597975A (en) 2009-07-09 2010-07-09 Methods and compositions for use in cellular therapies

Country Status (19)

Country Link
US (1) US8679834B2 (enExample)
EP (2) EP3150703A1 (enExample)
JP (1) JP5892931B2 (enExample)
KR (1) KR101788885B1 (enExample)
CN (2) CN107007626A (enExample)
AU (1) AU2010269962B2 (enExample)
BR (1) BR112012000534A2 (enExample)
CA (1) CA2767300C (enExample)
DK (1) DK2451943T3 (enExample)
ES (1) ES2479542T3 (enExample)
HU (1) HUE031921T2 (enExample)
IL (1) IL217377A (enExample)
MX (1) MX359639B (enExample)
NZ (1) NZ597975A (enExample)
PL (1) PL2451943T3 (enExample)
PT (1) PT2451943T (enExample)
RU (1) RU2610427C2 (enExample)
SG (2) SG177582A1 (enExample)
WO (1) WO2011004264A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
WO2007039150A2 (en) 2005-09-23 2007-04-12 Cellerix, S.L. Cell populations having immunoregulatory activity, method for isolation and uses
WO2011006029A1 (en) 2009-07-10 2011-01-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Artificial cell constructs for inducing immunological tolerance
US11090363B2 (en) 2009-07-10 2021-08-17 University of Pittsburgh—of the Commonwealth System of Higher Education Vasoactive intestinal peptide release from microparticles
JP6018081B2 (ja) * 2011-01-12 2016-11-02 ティジェニクス エス．エー．ユー． 自己免疫および炎症性疾患におけるリンパ系内投与用の脂肪由来間葉系幹細胞
TWI812867B (zh) 2011-11-30 2023-08-21 安斯泰來再生醫藥協會 利用血管母細胞產生間葉基質細胞之方法
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
EP2833896A2 (en) * 2012-03-30 2015-02-11 University Of Southern California Compositions and treatment methods for mesenchymal stem cell-induced immunoregulation
CA2876499C (en) 2012-07-12 2021-10-26 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
US10258652B2 (en) 2014-12-18 2019-04-16 Pluristem Ltd. Methods and compositions for treating and preventing muscle wasting disorders
WO2016107563A1 (zh) * 2014-12-29 2016-07-07 西比曼生物科技（上海）有限公司 一种用于治疗上呼吸道疾病的脂肪间充质祖细胞复合物
IL294058A (en) 2015-03-23 2022-08-01 Pluristem Ltd Use of adherent stromal cells for enhancing hematopoiesis in a subject in need thereof
US20210205370A1 (en) 2016-02-18 2021-07-08 Pluristem Ltd. Methods and compositions for treating cancers and neoplasms
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
WO2018002930A1 (en) 2016-06-30 2018-01-04 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
CA3062123A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells
CN110709091A (zh) 2017-05-15 2020-01-17 干细胞医药有限公司 使用长效格拉替雷和脂肪源性干细胞治疗多发性硬化症
CN107349419A (zh) * 2017-07-17 2017-11-17 广东颜值科技有限公司 一种细胞组合物及其制备方法和应用
CN107281469A (zh) * 2017-07-17 2017-10-24 广东颜值科技有限公司 一种细胞组合物及其制备方法和应用
EP3851112A4 (en) 2018-09-14 2022-07-27 Luca Science Inc. TRANSPLANTATION OF MITOCHONDRIA IN A LYMPHOID ORGAN AND ASSOCIATED COMPOSITION
EP3941495A4 (en) * 2019-03-19 2022-09-07 Figene, LLC TREATMENT OF CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY AND PULMONARY DEGENERATION USING ACTIVATED FIBROBLASTS AND EXOSOME DERIVATIVES THEREOF
US11878037B2 (en) 2019-05-31 2024-01-23 Figene, Llc Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
US20240000850A1 (en) * 2020-04-08 2024-01-04 Figene, Llc Methods and compositions for allergy and asthma treatment using fibroblasts

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2800113C (en) * 2002-07-12 2015-02-03 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
EP2260861A1 (en) * 2002-12-06 2010-12-15 NorthWest Biotherapeutics, Inc. Administration of dendritic cells partially matured in vitro for the treatment of tumors
WO2007039150A2 (en) 2005-09-23 2007-04-12 Cellerix, S.L. Cell populations having immunoregulatory activity, method for isolation and uses
US8241621B2 (en) * 2006-12-18 2012-08-14 Medistem Laboratories Stem cell mediated treg activation/expansion for therapeutic immune modulation
CA2697265A1 (en) * 2007-08-09 2009-02-19 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
JPWO2009031606A1 (ja) * 2007-09-07 2010-12-16 日本ケミカルリサーチ株式会社 関節炎治療及び予防剤
US20110150845A1 (en) * 2008-05-02 2011-06-23 Massachusetts Institute Of Technology Methods and compositions for modulating immunological tolerance
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells

Also Published As

Publication number Publication date
RU2012104529A (ru) 2013-08-20
CN107007626A (zh) 2017-08-04
US20120308585A1 (en) 2012-12-06
EP2451943B1 (en) 2016-11-23
PL2451943T3 (pl) 2017-04-28
US8679834B2 (en) 2014-03-25
AU2010269962B2 (en) 2016-04-14
JP5892931B2 (ja) 2016-03-23
IL217377A (en) 2017-10-31
WO2011004264A1 (en) 2011-01-13
SG10201403758SA (en) 2014-10-30
MX359639B (es) 2018-10-04
KR101788885B1 (ko) 2017-10-20
CA2767300C (en) 2020-01-07
PT2451943T (pt) 2017-01-20
EP3150703A1 (en) 2017-04-05
RU2610427C2 (ru) 2017-02-10
SG177582A1 (en) 2012-03-29
MX2012000396A (es) 2012-07-17
BR112012000534A2 (pt) 2017-06-13
CA2767300A1 (en) 2011-01-13
ES2479542T3 (es) 2017-05-26
IL217377A0 (en) 2012-02-29
EP2451943A1 (en) 2012-05-16
ES2479542T1 (es) 2014-08-20
HUE031921T2 (en) 2017-08-28
AU2010269962A1 (en) 2012-03-01
CN102549147A (zh) 2012-07-04
JP2012532859A (ja) 2012-12-20
DK2451943T3 (en) 2017-02-06
KR20120051006A (ko) 2012-05-21

Similar Documents

Publication Publication Date Title
NZ597975A (en) Methods and compositions for use in cellular therapies
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
MY185016A (en) Progenitor cells of mesodermal lineage
GB2482536B (en) Expression of antibody or a fragment thereof in lactobacillus
IN2015DN02826A (enExample)
MY165086A (en) Formulations of rifaximin and uses thereof
MX2011007647A (es) Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
MX2009009079A (es) Anticuerpos anti-il-23p19 de ingenieria.
MX2011009033A (es) Inhibidores triciclicos de cinasa pirazolopiridina.
MX2012000949A (es) Terapias de combinacion con moduladores de ck2.
IN2014DN06104A (enExample)
MX2012006320A (es) Composiciones de amantadina y metodos para su uso.
IL207310A0 (en) Vaccine compositions
MY170934A (en) Treatment of pain associated with dislocation of basal endometrium
TN2015000048A1 (en) Methods of administering rifaximin for weight loss and treatment of obesity
PH12013501163A1 (en) Compositions comprising a p13k inhibitor and a mek inhibitor and their use for treating cancer
MX2011009277A (es) Composicion de leucocito activada.
PH12014500739B1 (en) Methods for treating a stroke-related sensorimotor impairment using aminopyridines
WO2012006585A3 (en) Use of interleukin-15 to treat cardiovascular diseases
TW201612313A (en) Uses of ligustilide
MX2011007384A (es) Terapias de combinacion para trastornos neoplásticos.
GB201018154D0 (en) Method of treatment
TW201612314A (en) Uses of ligustilide for enhancing the efficacy of stem cells on treating autoimmune diseases, cardiovascular diseases, and/or hematological diseases
UA41936U (ru) Способ лечения крауроза вульвы в детском возрасте
AU336535S (en) Medical dressing

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: TIGENIX, S.A., ES

Effective date: 20130815

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 JUL 2017 BY CALLINANS

Effective date: 20150106

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2018 BY CPA GLOBAL

Effective date: 20170608

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2019 BY CPA GLOBAL

Effective date: 20180607

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2020 BY CPA GLOBAL

Effective date: 20190704

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2021 BY CPA GLOBAL

Effective date: 20200604

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2022 BY CPA GLOBAL

Effective date: 20210603

ASS Change of ownership

Owner name: TAKEDA PHARMACEUTICAL COMPANY, JP

Effective date: 20220121

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2023 BY ANAQUA SERVICES

Effective date: 20220621

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2024 BY ANAQUA SERVICES

Effective date: 20230620

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2025 BY ANAQUA SERVICES

Effective date: 20240619

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUL 2026 BY ANAQUA SERVICES

Effective date: 20250620